Navigation Links
Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
Date:9/22/2010

WALTHAM, Mass., Sept. 22 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Sachs Biotech in Europe Investor Forum Wednesday, September 29, 2010 at the Radisson Blu hotel in Zurich, Switzerland.

Dr. Horobin will be a panelist on the Oncology Investment Panel at 12:00 pm CEST.  Her presentation will be given at 5:00 p.m. CEST and will include an overview of upcoming milestones including the ongoing phase 2 clinical program for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

The presentation will be available at Syndax's website, www.syndax.com.

About SyndaxSyndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.

Syndax holds rights to entinostat from Bayer Schering Pharma and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.Contact InformationJoanna Horobin, M.D.

Danielle Bertrand Syndax Pharmaceuticals, Inc.

WCG Tel: 781-419-1402

Tel: 415-946-1056 jhorobin@syndax.com

dbertrand@wcgworld.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
3. Access Pharmaceuticals, Inc. Signs $30M MuGard Supply Agreement With RHEI Pharmaceuticals HK LTD.
4. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
5. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
6. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
7. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
8. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
9. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
10. Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
11. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report provides an extensive ... and focuses both on contract manufacturers and cell therapy developers ... as viable alternatives to conventional treatment options. ...
Breaking Medicine Technology:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research study, ... having the skills needed to execute that strategy, and the actual success of ...
(Date:3/27/2017)... ... ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from California ... she said. , She thinks the coming week is going to be a very joyful ... to help my students.” , The award will allow the 4th grade teacher at Tumwater ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. Angel Vitamins, ... a months-long rebranding effort. This includes the introduction of new packaging and messaging, ... market research, we learned that a simple, proactive approach to wellness is important ...
(Date:3/27/2017)... ... March 27, 2017 , ... The homeowner improvement and repair market ... utilizing DIY and unlicensed contractors for renovations is also on the rise. Per a ... 2015, and of those, 42% failed to use a licensed contractor.(2) The risks associated ...
(Date:3/25/2017)... , ... March 25, 2017 , ... Norland at Swissray is pleased to ... for large subjects. The ELITE DXA has an active scan window, which is more ... long to fit in the scan area could not undergo an accurate total body bone ...
Breaking Medicine News(10 mins):